1800 244 735

Helpline (02) 9874 9777

Getting the data out – a new scientific journal just for HD

The search for better treatments for HD requires a lot of effort by researchers across the globe. Time is of the essence: the ideal time for a treatment for HD is yesterday. Scientific findings need to be made available sooner rather than later, so that others can build on what is already known. PLoS Currents HD is a new journal launched to speed up the process of scientific discovery in HD.

Why is a new journal needed?

The traditional way to publish new findings is for researchers to send data with a ‘story’ to a scientific journal. A panel of experts then reviews that story, to judge whether the data and story are solid, and also whether the story is important enough to be interesting to the journal’s audience. This process is known as ‘peer review’.

This approach has advantages: it ensures that what is published is scientifically sound. Once published, articles can be retrieved via the internet through sites like PubMed, and used by other scientists to guide and advance their own research.

However, there are several drawbacks, too. Firstly, the time between doing the research and the story being published can be very long. Sometimes the story has to be offered to several journals, one after the other, before it is eventually published. Several years can pass like this.

Secondly, most journals survive by selling copies, so they have to rate the importance of each story. Anything that might not be interesting to that journal’s audience is likely to be rejected, even if the story is scientifically sound.

That introduces bias to what’s available in the scientific literature. It favours exciting stories, but makes it difficult publish solid, well-conducted scientific research if the results are less glamorous – for instance, if they show that a particular approach, idea or experiment has not helped. These are known as ‘negative results’.

Another problem is that a complete scientific ‘story’ might take five or ten years to research from start to finish. Along the way, interesting data might be produced, but because they don’t tell a complete story, they are unlikely to be published and seen by other researchers.

‘Negative data’, or data that don’t make a complete story, can still be really useful to other researchers. For science to make progress, knowing what doesn’t work can be as useful as knowing what does.

Imagine ten researchers in different places, working on similar scientific projects, that could have been shown to be pointless already, if someone had published a single negative result. All that effort, time and money could have been put to much better use.

How will PLos Currents HD help?

A new platform for publishing was launched in September 2010, aiming to make HD research more efficient by encouraging the publication of results that would otherwise never be seen, and shortening the time it takes to get data published.

This platform is called Public Library of Science (PLoS) Currents Huntington Disease and is supported by the CHDI fundation.

PLoS Currents HD aims to keep what’s good about conventional publishing: peer review, crediting researchers for their work, and making the research available online.

Its emphasis, though, is on getting scientific data into the public domain for everyone to access, not within years but within days. As a bonus, this way of publishing is cheap for researchers and offers free open-access for everyone wanting to use it – whether they’re scientists or not.

PLoS Currents Huntington Disease is edited by eminent HD researcher Gillian Bates. A board of expert moderators reviews new submissions, just like a conventional journal would. However, the reviewers make a decision based purely on whether the science is sound, and not whether the story is ‘important’ or ‘exciting’. After this quick check, the research is published immediately online. Because the process is so quick, findings may be available a few days after submission.

To improve interaction between researchers, readers can post comments, and the authors of articles can update their publications with new findings, so that various versions are available. Repeat submissions go through a review process to check that they are sound.

Hopefully, all this will make PLoS Currents HD a dynamic way to get good-quality data out into the public domain.

Here at HDBuzz, we believe that making scientific research available to everyone, quickly and reliably, is crucial to making progress. We’re confident that PLoS Currents will be a major step forward in the global search for treatments for HD.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more